As part of our ongoing series focussing on new registrations in Australia, we have added a product review of Remdesivir for the treatment of COVID-19. This review discusses current management and risk classification of COVID-19, available medicines and indications and dosage of Remdesivir together with the major studies featuring Remdesivir.
It also provides commentary and recommendations from Dr Krispin Hajkowicz, Director of the Infectious Diseases Unit at Royal Brisbane and Women’s Hospital, and Associate Professor, University of Queensland Centre for Clinical Research.
Please login below to download this issue (PDF)